News

Invokamet XR is a once-daily fixed-dose combination of canagliflozin and metformin hydrochloride extended release (XR) in two tablets for glycemic control in type 2 diabetics. The FDA approved

BAX 826 is an investigational, extended half-life recombinant Factor VIII (rFVIII) candidate based on the full length ADVATE [Antihemophilic Factor (Recombinant)] molecule. Baxalta plans to enroll 30 patients

The addition of C-103 provides a novel weight loss pharmaceutical product to the M Pharma pipeline. Indicative terms of the letter of intent include an up-front cash payment,

The Company received approval from the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND) application to begin the phase 2 clinical study in September.

Spring Bank chief medical officer Nezam Afdhal said: "Although medications like Viread® are excellent at suppressing HBV replication, ‘HBV cure’ has remained elusive. We are very excited to

BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate

The safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) is being evaluated in the study. Merck will sponsor the trail,

UCART19 uses Cellectis’ allogeneic approach to develop CAR-T therapies that engineer T-cells from non-patient donors for use in several patients. The immunotherapy candidate is about to enter Phase

The approval was based on data from pivotal Phase 3 ASPIRE trial which showed that patients treated with Kyprolis in combination lived nearly nine months longer without disease